相关实验视频

Updated: Jan 14, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

一个Naovel的库尔库明衍生物AN02调节了APC-SMAD4介导的CTLA-4降解,用于卵巢癌治疗

Hairong Jin¹, Mengjie Zhang², Mengna Shi³

¹Department of Obstetrics and Gynecology, The First Affiliated Hospital of Ningbo University, Ningbo, China.

Molecular carcinogenesis

|October 21, 2025

概括

一种新型的黄素衍生物AN02通过增强生物可用性和向APC-SMAD4-CTLA-4通路,对抗卵巢癌具有强大的抗瘤作用. 这种化合物显著抑制癌细胞的增殖和入侵,提供了有前途的治疗潜力.

科学领域:

自然产品化学自然产品化学
分子瘤学分子瘤学
药物发现药物发现药物发现

背景情况:

黄素是一种天然化合物,具有广泛的生物活性,但具有较差的生物利用性.
开发具有改善药理动力学特性和增强疗效的黄素衍生物对于临床应用至关重要.

研究的目的:

合成和评估一种新的黄素衍生物AN02,其在卵巢癌中的抗瘤潜力.
阐明AN02的有效性背后的分子机制,重点关注APC-SMAD4-CTLA-4轴.

主要方法:

合成AN02,一种新型的黄素衍生物.
在体外测试评估AN02对卵巢癌细胞增殖,入侵和迁移的影响.
涉及基因沉默和蛋白质相互作用分析的分子机制研究.
在小鼠体内使用皮下异种移植瘤模型的体内研究.

主要成果:

与黄素相比,AN02显著增强了口服吸收和生物可用性.
在低度下,AN02强烈抑制了卵巢癌细胞的增殖,入侵和迁移.
AN02通过激活腺多样性胆固醇 (APC) -SMAD4通路和抑制细胞毒性T-淋巴细胞相关蛋白4 (CTLA-4) 途径来起作用.
APC调节SMAD4-CTLA-4,SMAD4促进CTLA-4的降解,抑制卵巢癌的恶性病变.
在体内,AN02显著抑制了瘤生长.

结论:

AN02是一种有前途的黄素衍生物,对抗卵巢癌具有显著的抗瘤活性.
APC-SMAD4-CTLA-4分子轴是AN02治疗效果的一个关键目标.
AN02值得进一步研究,以作为一种新的卵巢癌治疗药物进行临床开发.

关键词:

这是APC的APC.在CTLA-4中,在SMAD4中,我们可以看到SMAD4.黄素的衍生品AN02 黄素的衍生品AN02 它们的扩散和扩散.

更多相关视频

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

相关概念视频

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...